US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Extraordinary General Meeting in Aerocrine AB

Aerocrine AB have today, 14 July 2015, held an extraordinary meeting. The following resolutions were made at the meeting. Annulment of resolution on the nomination committee At the Annual General Meeting held on 12 May 2015 it was resolved that the company's nomination committee shall consist of representatives from the four largest shareholders by voting powers  and the Chairman of the Board. Circassia Pharmaceuticals plc holds more than 90 per cent of the shares and votes in the company and therefore the meeting resolved to annul the resolution on the nomination committee.

Aerocrine is delisted today

As previously announced, today is the last day of trading in the Aerocrine stock on Nasdaq Stockholm. Following completion of the recent public tender offer, Circassia Pharmaceuticals Plc ("Circassia") has initiated a mandatory redemption procedure to acquire all shares not already held by Circassia. Further information on the redemption procedure will be sent to remaining shareholders within short.For more information, please contact: Scott Myers, Chief Executive Officer, Aerocrine AB, Phone: +1 970 368 0336 About Aerocrine Aerocrine AB is a medical products company focused on the

Aerocrine applies for delisting

The Board of Directors of Aerocrine AB (publ) (“Aerocrine”) has decided to apply for the delisting of the Aerocrine share from Nasdaq Stockholm. The last day of trading in the share is expected to be July 13, 2015.On June 15, 2015, Circassia Pharmaceuticals plc (“Circassia”) announced that the public offer to the shareholders of Aerocrine had been accepted to such an extent that Circassia now holds 92.6 percent of the shares and votes in Aerocrine. Circassia also announced its intention to request compulsory buy-out (tvångsinlösen) of the remaining shares in Aerocrine. In light of this,

Aerocrine Repays Loan Due to Change in Control

On June 15, 2015 Circassia Pharmaceuticals plc (“Circassia”) announced that 92.6% of the outstanding shares of Aerocrine had been tendered in Circassia’s public offer to the shareholders of Aerocrine and that the offer was declared unconditional. As noted in the statement by the Board of Directors of Aerocrine in relation to Circassia’s public offer issued on May 15, 2015, Aerocrine’s credit agreement with ROS Acquisition Offshore LP (an affiliate of OrbiMed Advisors LLC) and Novo A/S, dated April 29, 2013 contains change of control provisions, giving the lenders a right to declare

NOTICE TO EXTRAORDINARY GENERAL MEETING

The shareholders of Aerocrine Aktiebolag (publ) ("Aerocrine") are hereby invited to the Extraordinary General Meeting ("EGM") on Tuesday 14 July 2015 at 11 a.m. CET at Advokatfirman Cederquist's premises at Hovslagargatan 3, in Stockholm, Sweden.NOTIFICATION ETC. Shareholders who wish to attend the EGM shall          be recorded in the share register maintained by Euroclear Sweden AB on Wednesday 8 July 2015, and shall          notify the company of their intention to attend no later than by Wednesday 8 July 2015. Notice of attendance shall be made in writing to Aerocrine

Invitation to Aerocrine’s presentation at the Small Cap Day on June 8 in Stockholm

Aerocrine AB (Nasdaq Stockholm: AERO) hereby invites investors, analysts and the media to join a live web cast from the Small Cap Day in Stockholm.Scott Myers, CEO of Aerocrine, will inform about the Board’s recommendation to the shareholders to accept the public offer from Circassia and will do a company presentation of Aerocrine. The Small Cap Day is arranged by the Swedish Shareholders’ Association and Redeye on June 8 at Sheraton Hotel in Stockholm. The Aerocrine presentation will start at 14.50 CET and can be watched on: http://www.smabolagsdagen.net/live-sal-3/ For

Change in number of shares and votes in Aerocrine

With reference to Chapter 4 Section 9 in the Swedish Financial Instruments Trading Act, it is hereby announced that through the  subscription by a new share issue related to the company’s stock option program in Aerocrine AB (Nasdaq Stockholm: AERO), the number of shares and votes in Aerocrine has increased during May 2015 as specified in the table below. Number of shares and votesMay 1, 2015 698,766,052Increase 78,697May 29, 2015 698,844,749 Solna, May 29 2015 Aerocrine AB (publ.) For further

Statement by the Board of Directors of Aerocrine in relation to Circassia’s public cash offer

The Board of Directors of Aerocrine unanimously recommends Aerocrine’s shareholders to accept the offer by Circassia.NOT FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA), AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. Background This statement is made by the Board of Directors of Aerocrine AB (the “Board”) pursuant to Section II.19 of Nasdaq

Report from the 2015 Annual General Meeting in Aerocrine

The Annual General Meeting (AGM) in Aerocrine AB (Nasdaq Stockholm: AERO) was held on Tuesday, May 12, 2015, in SolnaThe parent company’s and the group’s income statements and balance sheets were adopted. It was resolved that no dividend shall be paid and that the year’s loss shall be carried forward. Rolf Classon, Lars Gustafsson, Dennis Kane, Michael Shalmi and Maria Strømme were re-elected as Board members. Lennart Johansson was elected as new Board member. Rolf Classon was re-elected as Chairman of the Board. Fees shall be payable to Board members with an amount of SEK 250,000 to

Aerocrine Sales Grow to Record Levels Again for 1st Quarter, NIOX VERO Launch in the US Off to A Strong Start

January – March 2015 · Net sales increased by 52% to SEK 53.2m (35.0)*. Adjusted for exchange rates, net sales increased by 31%.          - Clinical sales were SEK 38.9m, an increase of 32%.          - Global Research† sales were SEK 12.4m, an increase of 192%. · The launch of NIOX VERO in the US is progressing very well and the company projects to have phased out the majority of NIOX MINO devices before end of this year.  Quarter to date the US converted 310 NIOX VERO installations, but more importantly, the rate of conversions has been steadily accelerating with January at

Invitation to a teleconference/audiocast and presentation of Aerocrine’s Q1 Report 2015

Solna, Sweden – May 6, 2015 - Aerocrine AB (Nasdaq Stockholm: AERO) hereby invites to a teleconference/audiocast and presenting of Aerocrine’s first quarter result 2015 on May 12, 2015 at 09:30 CET. Aerocrine will publish its report for the first quarter 2015 on May 12, 2015. A teleconference/audiocast will be held for analysts, the media and investors on the same day at 09:30 CET. Scott Myers, CEO and Marshall Woodworth, CFO will present the report. The presentation will be held in English and it is possible to participate by teleconference or audiocast. The audiocast can be

Aerocrine AB responds to recent speculation in the market

SOLNA, Sweden - Aerocrine AB (OMX Nordic Exchange: AERO) responds to recent speculation in the market. Aerocrine has noted recent speculation in the markets. The Board of Aerocrine confirms that it is in preliminary discussions with a third party concerning a public offer for Aerocrine. There can be no certainty that an offer will be made, nor as to the terms of any such offer. A further announcement will be made in due course. For more information about Aerocrine: Scott Myers, Chief Executive Officer, Aerocrine AB, Phone: +1 970 368 0336 Marshall Woodworth, Chief Financial

Aerocrine: Sales start of NIOX VERO® in Japan

SOLNA, Sweden – Aerocrine AB (NASDAQ Stockholm: AERO) The marketing and sales efforts of Aerocrine’s FeNO measuring device NIOX VERO® was launched Sunday the 19th at an event held at the Swedish Embassy in Tokyo in the presence of the Swedish Trade Commissioner Cecilia Leiram and attended by more than 50 leading Japanese pulmonologists. “The start of NIOX VERO® sales in Japan today follows the introduction of our new FeNO measuring device, NIOX VERO®, in the US and Europe. Current sales of our device NIOX MINO® that was launched in Japan in November 2013 has been above expectations and

Changes in Aerocrine’s Executive Leadership Team

SOLNA, Sweden - April 16, 2015 - Aerocrine AB (Nasdaq Stockholm: AERO) is pleased to announce the following organizational changes: Morten Högholm Pedersen, MD PhD, will be joining the company in the role of Chief Technology Officer effective June 1st.  Morten comes to Aerocrine from GN Otometrics A/S in Denmark where he held a number of different positions, most recently as VP Global R&D and Product Management.  It is expected that his background in technology and technology development will further the development of the NIOX family of products including work currently underway to

Aerocrine publishes annual report for 2014

SOLNA, Sweden - 13 April, 2015 - Aerocrine AB (Nasdaq Stockholm: AERO) announces that the annual report for 2014 has been published. The complete annual report can be found on the Company website. See the link below: http://www.aerocrine.com/en/Investor-relations/Latest-annual-report/ For more information about Aerocrine please contact: Scott Myers, Chief Executive Officer, Aerocrine AB, Phone: +1 970 368 0336 Marshall Woodworth, Chief Financial Officer, Aerocrine AB: +1 919 749 8748 or +46 709 695 219 About Aerocrine Aerocrine AB is a medical products company focused

NOTICE OF ANNUAL GENERAL MEETING

The Annual General Meeting (“AGM”) in Aerocrine AB (publ) will be held on Tuesday May 12, 2015, 5.00 p.m. CET at Radisson Blu Royal Park Hotel, Frösundaviks allé 15 in Solna, Sweden.Right to attend and notice of attendance Shareholders who wish to attend the AGM must be recorded in the share register maintained by Euroclear Sweden AB on Wednesday May 6, 2015 and notify the company of their intention to attend by no later than Wednesday May 6, 2015, preferably before 3.00 p.m. CET. Notice of attendance is made in writing to Aerocrine AB, P.O. Box 1024, 171 21 Solna, Sweden, or by phone

Change in number of shares and votes in Aerocrine

With reference to Chapter 4 Section 9 in the Swedish Financial Instruments Trading Act, it is hereby announced that through the  subscription by a new share issue related to the company’s stock option program in Aerocrine AB (Nasdaq Stockholm: AERO), the number of shares and votes in Aerocrine has increased during March 2015 as specified in the table below. Number of shares and votesMarch 1, 2015 698,137,454Increase 629,598March 31, 2015 698,766,052 For further information, please contact: Marshall

AEROCRINE AB RECEIVES FDA CLEARANCE FOR NIOX VERO® BLUETOOTH® WIRELESS ENHANCEMENT

SOLNA, Sweden – March 6, 2015– Aerocrine AB (Nasdaq Stockholm: AERO) announces today that clearance was received for its FeNO measuring device to operate wirelessly with BlueTooth® technology in the US.The US FDA has granted Aerocrine AB regulatory clearance for NIOX VERO® through a special 510k to utilize BlueTooth® wireless technology to send FeNO measurements and patient data between the NIOX VERO and the healthcare providers’ computers.  This cordless enhancement allows the device to go with a healthcare provider to a patient regardless of setting, either in an examination room, a

Updated ownership structure after completion of the rights offering

SOLNA, Sweden - Aerocrine AB (Nasdaq Stockholm: AERO) updates information about its largest shareholders after a successful completion of the rights issue.  Novo A/S maintained their ownership position of 25.2 % and Invifed AB (part of Investor AB) increased their position to 24.8% according to Euroclear records as per February 20, 2015. “A strong and supportive shareholder base is a prerequisite for Aerocrine. We are pleased to see that our two largest owners put trust in Aerocrine’s future success.  Novo A/S maintained their ownership position of 25.2%. Invifed AB, part of Investor AB,

Change in number of shares and votes in Aerocrine etc.

With reference to Chapter 4 Section 9 in the Swedish Financial Instruments Trading Act, it is hereby announced that as a result of the recent rights issue in Aerocrine AB (Nasdaq Stockholm: AERO), the number of shares and votes in Aerocrine has increased during February 2015 as specified in the table below.  Number of shares and votesFebruary 1, 2015 155,416,387Increase 542,721,067February 27, 2015 698,137,454 It is further announced that Rolf Classon now has resumed his position as chairman of the

Aerocrine Achieves Record Sales for the 4th Quarter and Full Year

January – December 2014 · Net sales increased by 22% to SEK 166.2m (136.2)*. Adjusted for exchange rates, net sales increased by 16%. · Clinical sales were SEK 129.3m, an increase of 26%. · Global Research† sales were SEK 32.7m, an increase of 20%. · The Gross Margin for the period was 67% (72%)*. The reduction as compared to prior year was driven primarily by a change in channel mix as well as the write-down in Q4 of spare part inventory for the Company’s NIOX FLEX product, which is no longer being supported and of short-dated product, also during the fourth quarter.

Last day of trading in BTA brought forward

The last day for trading in paid subscribed shares (BTA) (ISIN SE0006593885) on Nasdaq Stockholm has been brought forward to February 16, 2015. The new shares created through conversion of the BTAs will commence trading on Nasdaq Stockholm as from February 18, 2015. For further information: Scott Myers, Chief Executive Officer, Aerocrine AB, Phone: +1 970 368 0336 or +46 768 788 379 Marshall Woodworth, Chief Financial Officer, Aerocrine AB: +1 919 749 8748 or +46 709 695 219 Or visit www.aerocrine.com About Aerocrine Aerocrine AB is a medical products company focused on

Final result of Aerocrine’s rights issue

NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONG KONG, JAPAN, CANADA, SINGAPORE, SOUTH AFRICA, THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL. The subscription period for Aerocrine AB’s (Nasdaq Stockholm: AERO) rights issue ended on January 28, 2015 and the final result shows that the rights issue is oversubscribed. The company will thereby receive approximately SEK 445 million before transaction costs. ”We are grateful for the continued support from current shareholders and

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Media